References

Ibrahim H, Maignel J, Hornby F, Daly D, Beard M. BoNT/A in the Urinary Bladder-More to the Story than Silencing of Cholinergic Nerves. Toxins (Basel). 2022; 14:(1) https://doi.org/10.3390/toxins14010053

Kestemont P, Hilton S, Andriopoulos B Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study. Aesthet Surg J. 2022; 42:(3)301-313 https://doi.org/10.1093/asj/sjab329

Robertson D. Challenges in prescribing practice. Journal of Prescribing Practice. 2022; 4:(5)188-189 https://doi.org/10.12968/jprp.2022.4.5.188

Solish MJ, Savinova I, Weinberg MJ. A Practical Approach to the Diagnosis and Treatment of Palmar Hyperhidrosis. Plast Reconstr Surg Glob Open. 2022; 10:(3) https://doi.org/10.1097/GOX.0000000000004172

Prescribing uses of botulinum toxin

02 June 2022
Volume 4 · Issue 6

Abstract

Deborah Robertson provides an overview of recently published articles that may be of interest to non-medical prescribers. Should you wish to look at any of the papers in more detail, a full reference is provided

Last month the research roundup provided you with an overview of articles that reported on some issues, barriers, and challenges in prescribing practice (Robertson, 2022). This month, we will be reviewing articles looking at the many and varied uses of botulinum toxin. The three articles reviewed examine the more commonly known area of prescribing for glabellar lines in aesthetic practice. The roundup will also consider the use of botulinum toxin for overactive bladder conditions and the management of hyperhidrosis. New areas for uses of botox continue to emerge and this review is not exhaustive in the conditions presented.

This article published in January 2022 in the journal Toxins sought to review the current evidence on Botulinum neurotoxin (BoNT/A) concerning its effect on bladder sensation and the potential mechanism by which it may have these effects (Ibrahmin et al, 2022). BoNT/A is one of a family of Botulinum toxins with this subtype, having known benefits in the treatment and management of many medical conditions, including cervical dystonia, strabismus and migraine. It exerts its primary effect on cholinergic neurones and prevents the exocytotic release of the neurotransmitter acetylcholine at neuromuscular junctions. However, this is not a complete answer as to how this may have effects on an overactive urinary bladder.

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month